Case‐control study evaluating competing risk factors for angioedema in a high‐risk population
Authors:
- David FosterDFDavid Foster
- Thomas J. OwTOThomas J. Ow
- 4 January 2016
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 126 (8) , 1823-1830
Abstract
Objectives/Hypothesis: Black race is a risk factor for angioedema. The primary aim was to examine the relationship between race–ethnicity and risk factors for angioedema.Study Design: Using a retrospective case‐control study design, data was extracted with the Clinical Looking Glass utility, a data collection and management tool that captures data from electronic medical record systems within the Montefiore Healthcare System. Cases were emergency department (ED) visits with primary or secondary International Classification of Diseases, Ninth Revision, code diagnoses of angioedema in adults aged ≥ 18 years from January 2008 to December 2013 at three Montefiore centers in Bronx, New York. Controls were a random sampling of adult ED visits during the same period.Methods: In primary analyses, angiotensin‐converting enzyme inhibitor (ACE‐I) and black race were evaluated for synergy. The influence of different risk factors in the development of angioedema was evaluated using logistic regression models. Finally, race–ethnicity was further explored by evaluating for effect modification by stratification of models by race–ethnicity categories.Results: There were 1,247 cases and 6,500 controls randomly selected from a larger control pool. ACE‐I use (odds ratio [OR] 3.70, 95% confidence interval [CI] 2.98, 4.60), hypertension (OR 1.88, 95% CI 1.55, 2.29), and black race (OR 2.25, 95% CI 1.86, 2.72) were the strongest risk factors. ACE‐I use and black race were not synergistic (OR 1.10, 95% CI 0.80, 1.51). Race–ethnicity was an effect modifier for certain risk factors.Conclusion: Race–ethnicity acts as an effect modifier for particular angioedema risk factors. The two strongest risk factors, ACE‐I use and black race, were not synergistic.Level of Evidence: 3b. Laryngoscope, 126:1823–1830, 2016Keywords
Funding Information
- National Center for Advancing Translational Sciences (NCATS)
- National Institutes of Health (NIH)
- Clinical and Translational Science Award (CTSA) (UL1 RR025750)
- NCATS (5KL2TR001071)
This publication has 32 references indexed in Scilit:
- Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004‐2007Allergy and Asthma Proceedings, 2011
- Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedemaPharmacogenetics and Genomics, 2010
- Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant useAllergy, 2010
- Increased Incidence of Angioedema with ACE Inhibitors in Combination with mTOR Inhibitors in Kidney Transplant RecipientsClinical Journal of the American Society of Nephrology, 2010
- Angiotensin converting enzyme inhibitor induced angio‐oedema: a review of the pathophysiology and risk factorsClinical & Experimental Allergy, 2009
- Ten-year study of causes of moderate to severe angioedema seen by an inpatient allergy/immunology consult serviceAllergy and Asthma Proceedings, 2008
- An evaluation of risk factors for adverse drug events associated with angiotensin‐converting enzyme inhibitorsJournal of Evaluation in Clinical Practice, 2004
- ACE Inhibitor‐Related Angioedema: Can Angiotensin‐Receptor Blockers Be Safely Used?The Journal of Clinical Hypertension, 2002
- Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedemaJournal of Allergy and Clinical Immunology, 2000
- Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to AllergensNew England Journal of Medicine, 1989